GS-5245 tablets 175 mg

DRUG2 trials

Sponsors

Gilead Sciences Inc.

Conditions

COVID-19Renal Impairment

Phase 1

A Phase 1 Open-label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Obeldesivir in Participants With Normal Renal Function and Renal Impairment

CompletedCTIS2023-504780-17-00

Gilead Sciences Inc.Renal Impairment

Start: 2024-03-19End: 2024-06-14Target: 10Updated: 2024-01-15

Phase 2

A Phase 2/3 Single-Arm, Open-label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Obeldesivir in Pediatric Participants With COVID-19

CompletedCTIS2023-503282-27-00

Gilead Sciences Inc.COVID-19

End: 2024-03-05Target: 22Updated: 2024-02-01